In recent years, Boron Neutron Capture Therapy (BNCT) has emerged as a cutting-edge cancer treatment technology, experiencing rapid development globally. Neuboron Medical Group (Neuboron), a leading company providing comprehensive BNCT solutions to the international market, possessing key core technologies, has developed China's first accelerator-based BNCT demonstration center in collaboration with Xiamen Humanity Hospital. The center conducted its first patient treatment under an Investigator Initiated Trial (IIT) in October 2022, making China the second country in the world capable of performing accelerator-based BNCT(AB-BNCT) treatments.
China's First AB-BNCT Treatment Equipment: NeuPEX Block-I and Integrated Diagnostic and Therapeutic Boron Drugs, Demonstrating Exceptional Performance and Quality
Neuboron has led the development of China's first AB-BNCT treatment equipment—NeuPEX Block-I and the first pair of integrated diagnostic and therapeutic boron drugs (18F-BPA and BPA). The NeuPEX system, designed with comprehensive consideration of clinical use scenarios, leads globally in multiple key indicators, including neutron beam utilization efficiency, treatment depth (11 cm), irradiation aperture (maximum 40 cm, with configurable collimators of various specifications), and the number of patients treated per year. Compared with similar Japanese products, Neuboron’s boron drug BPA is expected to have lower toxicity, better transportability, and easier storage, making it more suitable for widespread clinical use.
Xiamen Humanity Hospital’s NeuPEX System: Over 3 Years of Stable Operation, Over 40 Clinical Trials, and Over 50 Irradiation Treatments
Since its commissioning and beam output, the NeuPEX system at Xiamen Humanity Hospital has been stably supplying beams for over three years, successfully conducting irradiation experiments on cells, mice, rats, and beagles, as well as over 40 human clinical trials. Additionally, by collaborating with or undertaking research needs from top domestic and international universities and research institutions (such as Nanjing University of Aeronautics and Astronautics, China Pharmaceutical University, Istituto Nazionale di Fisica Nucleare, University of Pavia, etc.), it has carried out irradiation experiments for BNCT radiobiology, new drug research, and related topics. These efforts have fully validated the stability and reliability of the product, as well as demonstrated the efficiency and professionalism of Neuboron and Xiamen Humanity Hospital’s technical and clinical teams.
Initiation of China's First BNCT Drug-Device Combination Investigational New Drug(IND) Clinical Trial
In April 2024, Neuboron launched the Phase I IND clinical trial of its NeuPEX system and boron drugs at Xiamen Humanity Hospital, marking the first such project in China to enter the registration clinical stage. Following the completion of Phase I, Phase II IND clinical trial is scheduled to commence in 2025. Upon successful completion of the clinical trials and obtaining market approval, Neuboron will offer hospitals the world's leading BNCT tumor treatment technology, providing the full AB-BNCT system, related hardware components, and therapeutic boron drug BPA, offering new treatment options for cancer patients.
Through continuous technological innovation and clinical exploration, Neuboron has not only set a benchmark in China's BNCT field but also made significant contributions to the global development of BNCT technology. Looking ahead, Neuboron will accelerate the clinical market launch of BNCT in China, bringing advanced technology to more patients as soon as possible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204361462/en/